
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934

For the month of: August 2016

Commission File Number: 001-35776

ACASTI PHARMA INC.
(Name of Registrant)

545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.'s registration statement on Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ACASTI PHARMA INC.

Date: August 5, 2016

By: */s/ Mario Paradis*

Name: Mario Paradis

Title: VP & Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	Notice of Change in Fiscal Year End dated August 5, 2016



NOTICE OF CHANGE IN FISCAL YEAR END
Section 4.8 of National Instrument 51-102

TO: Autorité des marchés financiers
 Alberta Securities Commission
 British Columbia Securities Commission
 Manitoba Securities Commission
 Ontario Securities Commission

This Notice is provided pursuant to the requirements of Part 4.8 of National Instrument 51-102 – *Continuous Disclosure Obligations*.

1. Change of Financial Year End

Acasti Pharma Inc. (the "**Corporation**") has decided to change its fiscal year end from February 28 to March 31.

2. Reason for the Change

This step is being taken to allow the Corporation to be better aligned with its industry comparables and standard quarters.

3. Date of Old Financial Year End

February 28

4. Date of New Financial Year End

March 31

5. The length and ending date of the periods, including the comparative periods, of each interim financial report and the annual financial statements to be filed for the Corporation's transition year and its new financial year

Transition Year	Comparative Annual Financial Statements to Transition Year	New Financial Year	Comparative Annual Financial Statements to New Financial Year	Interim Periods for Transition Year	Comparative Interim Periods to Interim Periods in Transition Year	Interim Periods for New Financial Year	Comparative Interim Periods to Interim Periods in New Financial Year
13 months ended March 31, 2017	12 months ended February 29, 2016	March 31	13 months ended March 31, 2017	3 months ended May 31, 2016	3 months ended May 31, 2015	3 months ended June 30, 2017	3 months ended May 31, 2016
				6 months ended August 31, 2016	6 months ended August 31, 2015	6 months ended September 30, 2017	6 months ended August 31, 2016
				9 months ended November 30, 2016	9 months ended November 30, 2015	9 months ended December 31, 2017	9 months ended November 30, 2016
				13 months ended March 31, 2017	12 months ended February 29, 2016		

Dated this 5th day of August 2016

ACASTI PHARMA INC.

/s/ Jean-Daniel Bélanger
Jean-Daniel Bélanger
 Corporate Secretary
